GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases

$839,968
Robert McCullough Anthony · Massachusetts General Hospital · R01 · FY2020 · AI

Advancing treatment and understanding of immunotherapy in glioblastoma

$838,812
Nicholas A Butowski · University Of California, San Francisco · U19 · FY2025 · CA

Antiviral role of CD8+ T cells in ART-treated SIV-infected macaques

$837,286
Guido Silvestri · Emory University · R01 · FY2020 · AI

Spatiotemporal checkpoints of macrophages in aortic aneurysms- Renewal

$836,972
Bhama Ramkhelawon · New York University School Of Medicine · R01 · FY2024 · HL

Development of a potent and selective oral ENPP1 inhibitor for oncology

$836,231
Mohan Rao Kaadige · Stingray Therapeutics, Inc. · R44 · FY2023 · CA

Immune determinants modulating cancer development in Lynch Syndrome

$836,028
Nina Bhardwaj · Icahn School Of Medicine At Mount Sinai · UG3 · FY2025 · CA

Immune determinants modulating cancer development in Lynch Syndrome

$836,028
Nina Bhardwaj · Icahn School Of Medicine At Mount Sinai · UG3 · FY2024 · CA

Clinical trials employing cancer vaccine combination therapies

$835,822
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines

$835,822
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Identification of human tumor-associated antigens

$835,772
Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Polysaccharides In Morphogenesis

$835,507
Enrico Cabib · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2010 · DK

Antiviral role of CD8+ T cells in ART-treated SIV-infected macaques

$835,203
Guido Silvestri · Emory University · R01 · FY2019 · AI

Initiation Of DNA Replication In Mammalian Chromosomes

$834,809
Melvin Depamphilis · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2016 · HD

Radiation-induced translational control of gene expression

$834,513
Philip Tofilon · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Software for predicting liver injury from biologics drug candidates using data from a human liver microphysiology system

$834,404
Kyunghee Yang · Simulations Plus, Inc. · R44 · FY2023 · TR

Long-Term Cardiovascular Sequelae of Cancer Immunotherapies

$833,492
Javid J Moslehi · Vanderbilt University Medical Center · R01 · FY2021 · HL

Regulation of Ras-Dependent Signal Transduction Pathways

$832,699
Deborah Morrison · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis

$832,061
Justin M Balko · Vanderbilt University Medical Center · R01 · FY2021 · HL

MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies

$829,650
Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2022 · CA

MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies

$829,650
Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2018 · CA

MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies

$829,650
Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2021 · CA

MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies

$829,650
Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2019 · CA

MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies

$829,650
Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2020 · CA

A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy

$828,114
Gary Fanger · Rise Therapeutics, Llc · R44 · FY2023 · CA

Spatiotemporal checkpoints of macrophages in aortic aneurysms- Renewal

$826,506
Bhama Ramkhelawon · New York University School Of Medicine · R01 · FY2025 · HL